Enfusion (NYSE:ENFN) Sets New 1-Year High – Still a Buy?

Shares of Enfusion, Inc. (NYSE:ENFN) hit a new 52-week high during trading on Thursday . The stock traded as high as $11.80 and last traded at $11.38, with a volume of 160693 shares. The stock had previously closed at $11.07.

Analyst Ratings Changes

A number of research analysts have issued reports on ENFN shares. William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Stifel Nicolaus lifted their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, Piper Sandler raised their target price on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Enfusion has a consensus rating of “Hold” and an average target price of $10.50.

Enfusion Trading Up 1.3 %

The firm has a market cap of $1.48 billion, a P/E ratio of 287.45, a PEG ratio of 1.85 and a beta of 0.96. The company has a fifty day moving average price of $10.82 and a two-hundred day moving average price of $9.64.

Insider Buying and Selling at Enfusion

In other news, COO Neal Pawar sold 21,801 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the sale, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Bradley Herring sold 4,134 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $41,877.42. Following the sale, the chief financial officer now directly owns 266,369 shares of the company’s stock, valued at $2,698,317.97. This represents a 1.53 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 57,367 shares of company stock worth $591,335. Corporate insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

Several large investors have recently added to or reduced their stakes in the business. Mackenzie Financial Corp grew its stake in Enfusion by 4.8% during the fourth quarter. Mackenzie Financial Corp now owns 31,271 shares of the company’s stock worth $322,000 after purchasing an additional 1,434 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Enfusion by 43.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 33,721 shares of the company’s stock valued at $347,000 after acquiring an additional 10,173 shares during the period. Squarepoint Ops LLC grew its stake in Enfusion by 136.2% in the fourth quarter. Squarepoint Ops LLC now owns 35,633 shares of the company’s stock valued at $367,000 after acquiring an additional 20,550 shares during the period. State of Wyoming grew its stake in Enfusion by 52.7% in the fourth quarter. State of Wyoming now owns 76,814 shares of the company’s stock valued at $791,000 after acquiring an additional 26,525 shares during the period. Finally, Silvercrest Asset Management Group LLC acquired a new stake in Enfusion in the fourth quarter valued at approximately $4,300,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.